PROAIR HFA (albuterol sulfate) by Teva is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 2004.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
PROAIR HFA is a metered-dose inhaler (MDI) containing albuterol sulfate, a beta-2 adrenergic agonist that relaxes bronchial smooth muscle and improves airflow. It is indicated for the treatment and prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma. The drug works by stimulating adenyl cyclase to increase cyclic AMP, producing rapid bronchodilation with onset of improvement within 5 minutes and peak effect at approximately 1 hour.
Product approaching loss of exclusivity with modest Part D volume (12K claims), signaling transition from growth to maintenance mode with potential team consolidation.
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on PROAIR HFA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROAIR HFA roles are primarily commercial and defensive in nature, focused on maintaining market share, managing pricing pressure, and optimizing formulary access in a generic-threatened environment. Career progression on this product involves mastering market dynamics, stakeholder management, and strategic repositioning rather than driving innovation or volume growth.